Perceptive Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Perceptive Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$70.8M	Buy	7,434,033 +4,271,504	+135%	+$33.2M	1.38%	21
2025 Q4	$24.7M	Buy	+3,162,529	New	+$22.9M	0.44%	55
2017 Q1	–	Sell	-1,330,240	Closed	-$8.42M	–	167
2016 Q4	$8.42M	Buy	+1,330,240	New	+$6.92M	0.6%	41
2015 Q4	–	Sell	-123,745	Closed	-$1.41M	–	158
2015 Q3	$1.41M	Sell	123,745 -346,255	-74%	-$4.62M	0.11%	90
2015 Q2	$7.02M	Buy	+470,000	New	+$5.34M	0.42%	51
2014 Q1	–	Sell	-197,500	Closed	-$1.5M	–	130
2013 Q4	$1.5M	Buy	197,500 +6,912	+4%	+$43.8K	0.18%	59
2013 Q3	$1.39M	Buy	+190,588	New	+$967K	0.11%	66

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Perceptive Advisors's BCRX Position: Q1 2026 in Review

Perceptive Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 135% in Q1 2026, buying an estimated $33.2M and bringing the position to 7,434,033 shares worth $70.8M. The position accounts for 1.38% of the portfolio, ranked #21.

Perceptive Advisors first reported a position in BCRX in Q3 2013 and has held it in 7 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Perceptive Advisors held 7,434,033 shares of BioCryst Pharmaceuticals worth $70.8M as of Q1 2026.
Perceptive Advisors bought 4,271,504 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $33.2M.
BioCryst Pharmaceuticals made up 1.38% of Perceptive Advisors's portfolio in Q1 2026, its #21 holding.
Perceptive Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 7 quarters since.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.